TransCode Therapeutics In...

NASDAQ: RNAZ · Real-Time Price · USD
10.97
-0.08 (-0.72%)
At close: Aug 15, 2025, 3:59 PM
10.98
0.09%
After-hours: Aug 15, 2025, 03:59 PM EDT

TransCode Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
n/a n/a n/a n/a n/a 753.15K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost of Revenue
n/a n/a n/a n/a n/a 140.17K 138.78K 137.59K 100.2K 29.5K n/a 22.7K 21.6K 28.99K 7.54K 4.69K 1.25K
Gross Profit
n/a n/a n/a n/a n/a 612.97K -138.78K -137.59K -100.2K -29.5K n/a -22.7K -21.6K -28.99K -7.54K -4.69K -1.25K
Operating Income
-3.17M -5.09M -2.17M -5.11M -3.29M -4.06M -5.33M -5.13M -4.9M -5.53M -4.95M -4.71M -3.48M -2.99M -2.36M -355.53K -449.46K
Interest Income
146.00 159.00 179.00 178.00 168.00 137.00 131.00 246.00 4.77K 9.64K 9K 1.33K 442.00 510.00 141.00 n/a 12.00
Pretax Income
-12.09M -5.92M -2.32M -5.19M -3.33M -4.09M -5.3M -4.34M -4.82M -5.13M -4.29M -4.67M -3.47M -5.91M -2.33M 2.77M -4.49M
Net Income
-12.09M -5.92M -2.32M -5.19M -3.33M -4.09M -5.3M -4.34M -4.81M -18.41M -4.29M -4.64M -3.46M -8.83M -2.3M 5.9M -4.49M
Selling & General & Admin
951.65K 1.45M 938.02K 2.03M 1.53M 695.41K 1.98M 2.16M 2.31M 2.84M 1.91M 2.09M 1.6M 1.7M 1.37M 143.78K 185.71K
Research & Development
2.22M 3.64M 1.23M 3.08M 1.76M 3.36M 3.34M 2.97M 2.59M 2.69M 3.04M 2.62M 1.88M 1.5M 992.95K 211.75K 263.76K
Other Expenses
n/a n/a n/a n/a n/a 79.41K n/a n/a -79.41K -383.77K n/a -34.73K -6.99K 88.79K -31.73K -57.05K n/a
Operating Expenses
3.17M 5.09M 2.17M 5.11M 3.29M 3.92M 5.3M 4.34M 4.82M 5.14M 4.3M 4.67M 3.47M 3.28M 2.33M 298.48K 449.46K
Interest Expense
114.00 1.83K 10.79K 4.48K 9.71K 55.9K n/a 7.84K 13.43K n/a n/a n/a n/a n/a 333.00 41.97K 52.77K
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
3.17M 5.09M 2.17M 5.11M 3.29M 4.06M 5.3M 4.34M 4.82M 5.14M 4.3M 4.67M 3.47M 2.8M 2.33M 298.48K 449.46K
Income Tax Expense
n/a n/a n/a n/a n/a -3 27.44K n/a -4.77K 13.28M n/a -36.06K -7.43K 2.92M -30.2K -3.13M n/a
Shares Outstanding (Basic)
172.26K 356.12K 356.12K 213.67K 155.83K 5.37K 109.41K 30.49K 18.59K 486.66 16.22K 16.22K 16.22K 480.00 14.41K 14.96K 14.95K
Shares Outstanding (Diluted)
172.26K 356.12K 356.12K 213.67K 155.83K 5.37K 109.41K 30.49K 18.59K 486.66 16.22K 16.22K 16.22K 483.90 14.41K 14.96K 14.95K
EPS (Basic)
-70.28 -16.61 15.34 -24.42 -21.45 -761.16 -48.44 -142.38 -259.07 -37.83K -264.4 -288 -216 -18.4K -160 185.25 -300.1
EPS (Diluted)
-70.28 -16.61 15.34 -24.42 -21.45 -761.16 -48.44 -142.38 -259.07 -37.83K -264.4 -288 -216 -18.26K -160 185.25 -300.1
EBITDA
-12.03M -5.79M -2.18M -5.04M -3.18M -3.89M -5.16M -4.2M -4.72M -5.1M -4.26M -4.65M -3.45M -2.77M -2.32M 2.82M -4.43M
EBIT
-12.09M -5.91M -2.31M -5.19M -3.32M -4.03M -5.3M -4.33M -4.8M -5.13M -4.3M -4.67M -3.47M -2.8M -2.33M 2.81M -4.43M
Depreciation & Amortization
51.17K 122.86K 127.52K 142.83K 141.65K 140.17K 138.78K 137.59K 100.2K 29.5K 24.8K 22.7K 21.6K 28.99K 7.54K 4.69K 1.25K